Leroy Jones, MD
Urology · San Antonio, TXNPI 1518947613
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $334,613 of the $505,932 with a category attached, or 66.1%. Boston Scientific accounts for 91.4% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2019 at $127,488 and has fallen 60.1% since, to $50,842 in 2025. Among urology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 677 payments — averaging $747.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$463K
- Coloplast$29K
- Acerus Pharmaceuticals Corporation$6K
- EDAP Technomed Inc$4K
- Axonics, Inc.$2K
- Medtronic$1K
- plus $3K from 24 others
Across 16 payments — averaging $3154.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$50K
What the payments were for
- Consulting fees$98,06519%
- Speaking & faculty fees$334,61366%
- Travel & lodging$32,7496%
- Food & beverage$24,2015%
- Education$16,3053%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 492 | $462,538 |
| Coloplast | 52 | $28,619 |
| Acerus Pharmaceuticals Corporation | 7 | $5,806 |
| EDAP Technomed Inc | 9 | $3,594 |
| Axonics, Inc. | 10 | $1,608 |
| Medtronic | 7 | $1,139 |
| Endo Pharmaceuticals Inc. | 10 | $405 |
| Antares Pharma, Inc. | 34 | $330 |
| Johnson & Johnson | 7 | $321 |
| SN Holdings, LLC | 1 | $178 |
| Endo USA, Inc. | 3 | $146 |
| Novo Nordisk | 1 | $125 |
| Astellas Pharma US Inc | 7 | $123 |
| Teleflex LLC | 2 | $117 |
| Innovation Technologies Inc | 2 | $107 |
| Pfizer | 5 | $103 |
| Sumitomo Pharma America, Inc. | 4 | $82 |
| Calyxo, Inc. | 2 | $78 |
| AbbVie | 3 | $75 |
| Urogen Pharma, Inc. | 3 | $64 |
| Merck | 2 | $60 |
| Olympus America Inc. | 2 | $54 |
| Urovant Sciences Inc | 3 | $50 |
| Halozyme Inc | 2 | $46 |
| Tolmar, Inc. | 2 | $45 |
| Bayer | 1 | $27 |
| Procept Biorobotics Corporation | 1 | $25 |
| Ferring Pharmaceuticals Inc. | 1 | $23 |
| Dendreon Pharmaceuticals LLC | 1 | $23 |
| Progenics Pharmaceuticals, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMS$127,687
- GENERAL ERECTILE DYSFUNCTION$64,107
- AMS 700 CXR RTE KIT$45,049
- TITAN$27,361
- TACTRA$26,335
- AdVance XP$24,143
- GENERAL - THERAPIES$23,393
- AMS 800 Artificial Urinary Sphincter$14,586
- Natesto$5,730
- AMS 700$3,777
- AMBICOR$3,650
- ADVANCE$2,700
- Axonics$1,289
- Bulkamid$1,186
- INTERSTIM$994
- GENERAL MALE SUI$750
- XIAFLEX$239
- Erleada$150
- AKEEGA$150
- Balversa$150
How this compares
$505,932 in reported general payments places this provider in the 95th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 56 | $54,376 |
| GemtesaVibegron | 34 | $29,146 |
| Testosterone Cypionate | 71 | $4,644 |
| Tamsulosin Hcl | 304 | $4,223 |
| Trospium Chloride | 46 | $3,977 |
| Pentoxifylline | 42 | $2,102 |
| Finasteride | 71 | $1,230 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 49 | $917 |
| Cabergoline | 15 | $315 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 50 | $274 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 53 | $258 |
| Sildenafil Citrate | 17 | $105 |
| Ciprofloxacin Hcl | 14 | $93 |
| Tramadol Hcl | 17 | $42 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $123 | $54,37656 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $82 | $29,14634 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 878 urology providers in Texas.
Other urology in San Antonio
- Daniel SaltzsteinSan Antonio$547K
- Jose de la CerdaSan Antonio$278K
- Naveen KellaSan Antonio$84K
- Christopher CantrillSan Antonio$73K
- Robert SvatekSan Antonio$51K
- Andrew von EschenbachMontgomery$3.2M
- Brian MazzarellaLakeway$1.2M
- Arun RaiHouston$920K
- Allen MoreyDallas$914K
- Donald GriffithHouston$732K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.